Abstract
With cone beam computed tomography (CBCT) in image guided radiation therapy being amongst the most widely used imaging modalities, there has been an increasing interest in quantifying the concomitant dose and risk. Whilst there have been several studies on this topic, there remains a lack of standardisation and knowledge on dose variations and the impact of patient size. Recently, PCXMC (a Monte Carlo simulator) has been used to assess both the concomitant dose and dosimetric impact of patient size variations for CBCT. The scopes of these studies, however, have included only a limited range of imaging manufacturers, protocols, and patient sizes. An approach using PCXMC and MATLAB was developed to enable a generalised method for rapidly quantifying and formulating the concomitant dose as a function of patient size across numerous CBCT vendors and protocols. The method was investigated using the Varian on board imaging 1.6 default pelvis and pelvis spotlight protocols, for 94 adult and paediatric phantoms over 6 age groups with extensive height and mass variations. It was found that dose varies significantly with patient size, as much as doubling and halving the average for patients of lower and higher mass, respectively. These variations, however, can be formulated and accounted for using the method developed, across a wide range of patient sizes for all CBCT vendors and protocols. This will enable the development of a comprehensive catalogue to account for concomitant doses in almost any clinically relevant scenario.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.